Amneal Pharmaceuticals (AMRX) vs Ligand Pharmaceuticals (LGND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed Ligand Pharmaceuticals (LGND) over the past year, gaining 89.7% versus a gain of 60.1%. Over five years, LGND leads with a +260.9% price change compared with +248.4% for AMRX. Amneal Pharmaceuticals is the larger company by market cap ($6.74 billion vs $5.77 billion), about 1.2 times the size, while Ligand Pharmaceuticals is growing revenue faster (+60.4% vs +8.0%).
On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (16.2x vs 24.2x for Ligand Pharmaceuticals). Ligand Pharmaceuticals converts more of its revenue into profit, with a net margin of 46.4% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | LGND |
|---|---|---|
| Share price | $19.35 | $289.62 |
| Market cap | $6.74B | $5.77B |
| 1-day change | -1.55% | -1.24% |
| YTD return | +55.95% | +55.11% |
| 1-year return | +89.67% | +60.11% |
| 5-year return | +248.40% | +260.89% |
| P/E ratio (TTM) | 39.48 | 30.52 |
| Forward P/E | 16.22 | 24.24 |
| EPS (TTM) | $0.49 | $9.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $268.09M |
| Revenue growth (YoY) | +8.05% | +60.40% |
| Net income (latest FY) | $72.06M | $124.45M |
| Gross margin | 36.88% | — |
| Operating margin | 13.05% | 15.29% |
| Net margin | 2.39% | 46.42% |
| 52-week high | $21.18 | $326.63 |
| 52-week low | $9.56 | $175.89 |
| Distance from 52-week high | -8.64% | -11.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +17.39% | +18.86% |
| Average volume | 2.26M | 262.72K |
| Shares outstanding | 348.30M | 19.94M |
| Employees | 8,700 | 47 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed LGND by 29.6 percentage points over the past year.
- Amneal Pharmaceuticals trades at a higher earnings multiple (39.5x vs 30.5x trailing P/E).
- Ligand Pharmaceuticals is more profitable, keeping 46.4 cents of every revenue dollar as net income versus 2.4 cents for Amneal Pharmaceuticals.
- Ligand Pharmaceuticals grew revenue faster in its latest fiscal year (+60.40% vs +8.05%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
AMRX vs LGND FAQ
Which is bigger, Amneal Pharmaceuticals or Ligand Pharmaceuticals?
Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $6.74B compared with $5.77B for Ligand Pharmaceuticals (LGND).
Which stock has performed better over the past year, AMRX or LGND?
AMRX returned +89.67% over the past 12 months, compared with +60.11% for LGND (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMRX or LGND?
LGND has the lower trailing P/E at 30.5, versus 39.5 for AMRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amneal Pharmaceuticals and Ligand Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.